Pilot study of DNA methylation, molecular aging markers and measures of health and well-being in aging
- PMID: 30886137
- PMCID: PMC6423054
- DOI: 10.1038/s41398-019-0446-1
Pilot study of DNA methylation, molecular aging markers and measures of health and well-being in aging
Abstract
Relations of DNA methylation markers to other biological aging markers and to psychosocial, behavioral, and health measures remain unclear. The sample included 23 participants (n = 11 cases with psychiatric diagnoses and n = 12 controls without current or lifetime psychiatric disorder), balanced by age and sex. Genomic DNA was extracted from blood samples; the following were performed: genome-wide DNA methylation assay using Illumina 850k methylationEPIC; PCR assays for relative telomere length (RTL) and mitochondrial DNA copy number (mtCN). Exposures were: case status; depression and anxiety symptoms; psychosocial support; subjective and objective cognition. Outcomes were: DNA methylation age (DNAm age); RTL; mtCN; extrinsic and intrinsic epigenetic age acceleration (EEAA and IEAA). Stronger correlation with chronological age was observed for DNAm age (ρ = 0.86; p < 0.0001) compared to RTL (ρ = -0.53; p < 0.01); mtCN was not correlated with age. DNAm age was more strongly correlated with behavioral and health variables than RTL or mtCN; e.g., correlations with DNAm age: body mass index (ρ = 0.36; p = 0.10); smoking pack-years (ρ = 0.37; p = 0.08); physical activity (ρ = -0.56; p = 0.01); alcohol intake (ρ = 0.56; p = 0.01). DNAm age was inversely correlated with psychosocial support (ρ = -0.42; p = 0.048) and Modified Mini-Mental State score (ρ = -0.44; p = 0.01). Anxiety, psychosocial support, and objective cognition were significantly related to accelerated aging; depression and subjective cognition were not. In conclusion, DNAm age correlated more strongly with chronological age and key psychosocial, behavioral, and health variables than RTL or mtCN. Signals for associations with epigenetic aging were observed for psychosocial and neurobehavioral variables.
Conflict of interest statement
D.M. has received research support from Nordic Naturals. He has provided unpaid consulting for Pharmavite LLC and Gnosis USA, Inc. He has received honoraria for speaking from the Massachusetts General Hospital Psychiatry Academy and from Blackmores. He has received royalties from Lippincott Williams & Wilkins for published book “Natural Medications for Psychiatric Disorders: Considering the Alternatives.” O.I.O. receives royalties from Springer Publishing for a book on late-life depression prevention. C.F.R. receives payment from the American Association of Geriatric Psychiatry as editor of the American Journal of Geriatric Psychiatry and royalty income for intellectual property as co-inventor of the Pittsburgh Sleep Quality Index. The remaining authors declare that they have no conflict of interest.
Figures




References
Publication types
MeSH terms
Substances
Grants and funding
- R01 AG036755/AG/NIA NIH HHS/United States
- P30 MH090333/MH/NIMH NIH HHS/United States
- R01 HL102122/HL/NHLBI NIH HHS/United States
- U01 CA138962/CA/NCI NIH HHS/United States
- R01 MH096776/MH/NIMH NIH HHS/United States
- R01 CA138962/CA/NCI NIH HHS/United States
- R01 AR059086/AR/NIAMS NIH HHS/United States
- R01 DK088762/DK/NIDDK NIH HHS/United States
- R01 AR060574/AR/NIAMS NIH HHS/United States
- R01 DK088078/DK/NIDDK NIH HHS/United States
- R01 MH091448/MH/NIMH NIH HHS/United States
- R01 HL101932/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases